Xeris Biopharma (XERS) Barclays 28th Annual Global Healthcare Conference summary

Company overview and product portfolio

• Operates as a fast-growing commercial biopharma with three marketed products: Gvoke, KEVEYIS, and RECORLEV.

• Gvoke targets hypoglycemia, KEVEYIS addresses primary periodic paralysis, and RECORLEV treats hypercortisolemia/Cushing's syndrome.

• Pipeline includes XP-8121, a once-weekly SubQ levothyroxine for hypothyroidism, phase III-ready and expected to start trials this year.

Financial performance and growth

• Achieved $292 million in revenue for 2025, representing 44% growth and surpassing guidance.

• Delivered $60 million in adjusted EBITDA and reported net income for the full year.

• Transitioned to self-funding strategy, supporting both pipeline and future growth.

Product performance and market dynamics

• RECORLEV experienced over 100% growth for two consecutive years, driven by increased diagnosis and expanded sales force.

• Gvoke continues steady growth, focusing on increasing patient adoption among those at risk for hypoglycemia.

• KEVEYIS remained resilient despite generic competition, returning to growth in 2025 with patient support services offsetting pricing pressures.